Edwards Lifesciences CorpEW
▲ PositiveCapitalrelevance
Reported 12.5% sales growth, raised guidance, and strong margins.
Impact on stocks 1
Aging Population
Edwards Lifesciences CorpEdwards Lifesciences reported second-quarter 2026 total sales of $1.74 billion, a 12.5% increase year-over-year, driven by growth across its TAVR, mitral, tricuspid, and surgical segments. TAVR sales reached $1.3 billion, up 10.5%, while TMTT sales surged 44.8% to $195.9 million, and surgical sales rose 5% to $284 million. Adjusted earnings per share were $0.78, with an adjusted gross profit margin of 77.6% and an adjusted operating profit margin of 30%. The company raised its full-year 2026 sales growth guidance for TAVR, TMTT, and total company, and held approximately $2.9 billion in cash and equivalents as of June 30, 2026, with $1.5 billion remaining under its share repurchase authorization.
Edwards Lifesciences CorpReported 12.5% sales growth, raised guidance, and strong margins.